Vera Therapeutics, Inc.

NASDAQ:VERA

Biotechnology

Healthcare
$25.58 +0.27%

+$0.09 today

Market cap
$1.85B
Beta
0.95
P/E (TTM)
-6.8
EPS (TTM)
-$5.16
52W Low $19.07High $56.05

Volume 0.95M

Average 1.18M

VERA Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Vera Therapeutics, Inc.NASDAQ: VERA

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents broadly unchanged from a year ago

Cash & equivalents stood at $48.88M at the end of Q2 FY2026, down 0.5% from a year earlier and down 57.3% from the prior quarter. Over 3 fiscal years it compounded at +101.3% a year.

Context

  • Cash & equivalents amounted to 9.2% of total assets at the end of Q2 FY2026, up 0.7 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -0.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$48.88M-57.3% QoQ
Last fiscal yearDec 2025
$354.73M+282.9% YoY
Year agoJun 2025
$49.12M-0.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.5%——
1 year+282.9%——
3-year CAGR+101.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
354.73M USD
Year-over-year change
+282.9%
4-year CAGR
+45.3%

Cash & Equivalents vs competitors

How VERA compares with its peers on the latest reported figures

  • VERA's Jun 2026 cash & equivalents of $48.88M is the 7th highest of the 10 companies compared; the peer median is $63.71M.
  • Its year-over-year change of -0.5% is the 5th highest of 10, against a peer median of -5.6%.
  • Cash & equivalents amounts to 9.2% of total assets for VERA, versus a peer median of 12.5%.
VERA Competitors Peer median
Cash & Equivalents for VERA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MLTXMoonLake ImmunotherapeuticsMar 2026$298.49M +9.9%+103.8%74.6%
ANABAnaptysBio, Inc.Mar 2026$248.47M +151.9%+49.5%75.4%
BHVNBiohaven Ltd.Jun 2026$238.03M +43.6%+3.9%64.2%
DNTHDianthus Therapeutics, Inc.Jun 2026$110.55M +735.2%+49.3%9.1%
ALMSAlumis Inc. Common StockJun 2026$63.71M -58.0%+51.8%11.4%
PHARPharming Group N.V.Mar 2026$53.1M -11.6%-11.0%10.9%
VERAVera Therapeutics, Inc.Jun 2026$48.88M -0.5%+101.3%9.2%
ARQTArcutis Biotherapeutics, Inc.Jun 2026$34.12M -53.3%-7.2%7.0%
KYTXKyverna Therapeutics, Inc.Mar 2026$32.19M -43.4%+48.7%12.5%
ACRSAclaris Therapeutics, Inc.Mar 2026$28.66M -5.6%-23.9%14.4%
Peer median (excluding VERA) $63.71M-5.6%+48.7%12.5%

Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents79.67M43.46M45.68M92.65M354.73M
Short-term Investments071.19M115.04M548.21M359.86M
Net Receivables0003.77M3.29M
Inventory00000
Other Current Assets480K719K3.22M913K2.54M
Total Current Assets82.54M125.7M172.02M651.22M728.88M
Property, Plant & Equipment (Net)05.22M3.04M4.33M1.92M
Goodwill00000
Intangible Assets00000
Long-term Investments867K58K11K00
Tax Assets00000
Other Non-current Assets344K455K471K131K3.93M
Total Non-current Assets1.21M5.74M3.52M4.46M5.85M
Total Assets83.75M131.44M175.55M655.68M734.73M
Account Payables1.39M11.99M11.12M7.67M21.9M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities377K04.82M01.37M
Total Current Liabilities7.69M25.6M22.3M25.37M53.46M
Long-term Debt4.92M24.81M49.88M50.69M74.84M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.54M286K286K00
Total Non-current Liabilities6.47M28.93M51.56M53.16M76.76M
Total Liabilities14.16M54.53M73.86M78.53M130.21M
Common Stock21K28K44K64K71K
Retained Earnings(124.06M)(213.11M)(309.1M)(461.25M)(760.87M)
Accumulated OCI(0)(224K)251K393K786K
Other Stockholders Equity00000
Minority Interest00000
Total Equity69.59M76.91M101.69M577.16M604.52M
Total Debt4.92M31.29M53.71M54.64M77.31M
Net Debt(74.75M)(12.17M)8.03M(38.01M)(277.42M)

Vera Therapeutics, Inc.

NASDAQ:VERA

Intrinsic Alpha fair value

Locked

Current Price

$25.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.